Renal impairment
(CrCl 15−50 ml/min)
Your choice for ageing
patients with NVAF
What is LIXIANA® indicated for?
LIXIANA® is indicated for:1 prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)
Superior reduction
in major bleeding
vs. well-managed warfarin2
Efficacy and safety profile
even when used with appropriate dose reduction2
Once-daily dosing with or without food
in NVAF1
In patients with NVAF and high CrCl, there is a trend towards decreasing efficacy with increasing CrCl for edoxaban vs well-managed warfarin, therefore careful evaluation of thromboembolic and bleeding risk is necessary before initiation.
LIXIANA® demonstrated superior reduction in major bleeding vs. well-managed warfarin2*
In the safety-on-treatment population
the annualised rate of major bleeding events with once-daily LIXIANA® vs. well-controlled warfarin was: 2.75% vs 3.43%2*
HR 0.80; 95% CI, 0.71 to 0.91; P<0.001
Read about the ENGAGE AF-TIMI 48 trial. The longest DOAC trial to date in NVAF
Real-world evidence reinforces LIXIANA® as your DOAC of choice for ageing patients with NVAF3,4
Data from a 1-year snapshot analysis of an ongoing observational study in 12,574 patients with NVAF (ETNA-AF** Europe),1 treated with once-daily LIXIANA® (edoxaban), reinforced the findings of the pivotal phase 3 study (ENGAGE-AF† European Cohort).2,4
LIXIANA® – simple and convenient once-daily dosing in NVAF5
60mg Standard dose
The recommended dose of LIXIANA® is 60 mg once-daily. It can be taken with water, with or without food. To aid compliance, patients should be encouraged to take their dose at the same time every day.
30mg Reduced dose
A dose of 30 mg once daily is required for certain patients who fall into specific sub-groups.
Recommended for patients with one or more of the following factors that increase risks of bleeding:1
Low body weight
(≤60 kg)
Concomitant use of potent P-gp inhibitors
(dronedarone, erythromycin, ketoconazole, ciclosporin)
Can be taken with or without food1
Not significantly affected by CYP450 inducers/inhibitors
(<10% is metabolised by CYP3A4/5)1
Rapid onset of anticoagulant therapeutic effect
(1-2 hours)1
No routine anticoagulation level monitoring required1
Lactose not listed as an excipient5††
In patients with NVAF and high CrCl, there is a trend towards decreasing efficacy with increasing CrCl for edoxaban vs well-managed warfarin, therefore careful evaluation of thromboembolic and bleeding risk is necessary before initiation.
For more information on how to use LIXIANA® please download our practical guide
References
- LIXIANA® Summary of Product Characteristics.
- Giugliano RP et al. NEJM 2013;369(22):2093–2104 and supplementary appendix.
- De Groot JR et al. presented at ESC 2019. Poster 4756
- De Caterina R et al. presented at ESC 2019. Poster 1257
- LIXIANA® Patient Information Leaflet.
- Schulman S and Kearon C. J Thromb Haemost 2005;3(4):692–694